Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Schrör K[au]:

Aspirin and lipid mediators in the cardiovascular system. Schrör K et al. Prostaglandins Other Lipid Mediat. (2015)

Aspirin and Reye syndrome: a review of the evidence. Schrör K et al. Paediatr Drugs. (2007)

Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Schrör K et al. Semin Thromb Hemost. (1997)

Search results

Items: 1 to 50 of 399

1.

Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.

Schrör K, Kristensen SD, Storey RF, Verheugt FWA.

Thromb Haemost. 2019 Oct;19(10):1573-1582. doi: 10.1055/s-0039-1694774. Epub 2019 Aug 20.

PMID:
31430800
2.

Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options.

Trenk D, Hille L, Leggewie S, Stratz C, Nührenberg TG, Aradi D, Schrör K, Sibbing D.

Thromb Haemost. 2019 Oct;19(10):1606-1616. doi: 10.1055/s-0039-1693738. Epub 2019 Aug 13.

PMID:
31408901
3.

[Importance of acetylsalicylic acid in primary prevention : ASCEND, ARRIVE and ASPREE as well as a meta-analysis by Rothwell et al.]

Schrör K, Nitschmann S.

Internist (Berl). 2019 Feb;60(2):209-216. doi: 10.1007/s00108-018-0541-z. Review. German. No abstract available.

PMID:
30645666
4.

Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?

Fender AC, Rauch BH, Geisler T, Schrör K.

Thromb Haemost. 2017 Nov;117(11):2013-2025. doi: 10.1160/TH17-03-0219. Epub 2017 Nov 30. Review.

PMID:
29044290
5.

[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)].

Schrör K, Nitschmann S.

Internist (Berl). 2017 Aug;58(8):863-865. doi: 10.1007/s00108-017-0260-x. German. No abstract available.

PMID:
28534137
6.

[Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].

Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bänsch D, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC.

Herzschrittmacherther Elektrophysiol. 2016 Sep;27(3):295-306. doi: 10.1007/s00399-016-0447-1. Review. German.

PMID:
27576696
7.

Sphingosine-1-Phosphate and Its Receptors: A Mutual Link between Blood Coagulation and Inflammation.

Mahajan-Thakur S, Böhm A, Jedlitschky G, Schrör K, Rauch BH.

Mediators Inflamm. 2015;2015:831059. doi: 10.1155/2015/831059. Epub 2015 Oct 29. Review.

8.

Aspirin in the 21st century-common mechanisms of disease and their modulation by aspirin: a report from the 2015 scientific conference of the international aspirin foundation, 28 August, London, UK.

Smith T, Hutchison P, Schrör K, Clària J, Lanas A, Patrignani P, Chan AT, Din F, Langley R, Elwood P, Freedman A, Eccles R.

Ecancermedicalscience. 2015 Oct 13;9:581. doi: 10.3332/ecancer.2015.581. eCollection 2015.

9.

Platelets, inflammation and anti-inflammatory drugs in ACS and CAD.

Schrör K, Huber K.

Thromb Haemost. 2015 Aug 31;114(3):446-8. doi: 10.1160/TH15-08-0632. Epub 2015 Aug 20. Review. No abstract available.

PMID:
26288949
10.

Aspirin and lipid mediators in the cardiovascular system.

Schrör K, Rauch BH.

Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):17-23. doi: 10.1016/j.prostaglandins.2015.07.004. Epub 2015 Jul 19. Review.

PMID:
26201059
11.

Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?

Hohlfeld T, Schrör K.

Thromb Haemost. 2015 Aug 31;114(3):469-77. doi: 10.1160/TH15-03-0191. Epub 2015 Jun 18. Review.

PMID:
26085050
12.

Why we should not skip aspirin in cardiovascular prevention.

Schrör K.

Hamostaseologie. 2016;36(1):33-43. doi: 10.5482/hamo-14-10-0048. Epub 2015 Apr 20. Review.

PMID:
25891122
13.

Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects.

Polzin A, Richter S, Schrör K, Rassaf T, Merx MW, Kelm M, Hohlfeld T, Zeus T.

Thromb Haemost. 2015 Jul;114(1):87-95. doi: 10.1160/TH14-11-0922. Epub 2015 Mar 19.

PMID:
25789542
14.

Inhibition of antiplatelet effects of aspirin by nonopioid analgesics.

Hohlfeld T, Schrör K.

Clin Pharmacol Ther. 2015 Feb;97(2):131-4. doi: 10.1002/cpt.21. Epub 2014 Dec 15.

PMID:
25670517
15.

[Aspirin and venous thromboses].

Schrör K.

Internist (Berl). 2015 Jan;56(1):84-90. doi: 10.1007/s00108-014-3622-7. Review. German.

PMID:
25576252
16.

[Perioperative aspirin treatment in patients undergoing surgery: Perioperative Ischemic Evaluation 2 (POISE-2)].

Schrör K, Nitschmann S.

Internist (Berl). 2014 Dec;55(12):1492-4. doi: 10.1007/s00108-014-3621-8. German. No abstract available.

PMID:
25398476
17.

Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus.

Pavic G, Grandoch M, Dangwal S, Jobi K, Rauch BH, Doller A, Oberhuber A, Akhyari P, Schrör K, Fischer JW, Fender AC.

Circulation. 2014 Nov 4;130(19):1700-11. doi: 10.1161/CIRCULATIONAHA.113.007590. Epub 2014 Sep 19.

PMID:
25239438
18.

How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; European Platelet Academy.

Thromb Haemost. 2015 Jan;113(1):37-52. doi: 10.1160/TH14-03-0238. Epub 2014 Sep 18. Review.

PMID:
25231675
19.

Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes.

Mahajan-Thakur S, Sostmann BD, Fender AC, Behrendt D, Felix SB, Schrör K, Rauch BH.

J Leukoc Biol. 2014 Oct;96(4):611-8. doi: 10.1189/jlb.3AB1013-567R. Epub 2014 Jul 2.

PMID:
24990321
20.

[Aspirin in primary and secondary prevention of colorectal carcinomas].

Schrör K, Rauch B.

Med Monatsschr Pharm. 2013 Nov;36(11):411-21. Review. German.

PMID:
24640118
21.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

22.

Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction.

Polzin A, Rassaf T, Böhm A, Lüth A, Kleuser B, Zeus T, Kelm M, Kroemer HK, Schrör K, Rauch BH.

Int J Cardiol. 2013 Dec 10;170(2):e23-4. doi: 10.1016/j.ijcard.2013.10.050. Epub 2013 Oct 16. No abstract available.

PMID:
24169533
23.

Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease.

Polzin A, Zeus T, Schrör K, Kelm M, Hohlfeld T.

J Am Coll Cardiol. 2013 Oct 29;62(18):1725-1726. doi: 10.1016/j.jacc.2013.07.039. Epub 2013 Aug 14. No abstract available.

24.

[Aspirin and prevention of colorectal carcinomas].

Schrör K, Rauch BH.

Internist (Berl). 2013 Jul;54(7):884-91. doi: 10.1007/s00108-013-3311-y. German.

PMID:
23784600
25.

Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells.

Böhm A, Flößer A, Ermler S, Fender AC, Lüth A, Kleuser B, Schrör K, Rauch BH.

Cardiovasc Res. 2013 Aug 1;99(3):505-13. doi: 10.1093/cvr/cvt112. Epub 2013 May 7.

PMID:
23658376
26.

High on-treatment platelet reactivity--why should we be concerned?

Huber K, Schrör K.

Thromb Haemost. 2013 May;109(5):789-91. doi: 10.1160/TH13-04-0281. Epub 2013 Apr 11. No abstract available.

PMID:
23576102
27.

Expression and translation of the COX-1b gene in human cells--no evidence of generation of COX-1b protein.

Reinauer C, Censarek P, Kaber G, Weber AA, Steger G, Klamp T, Schrör K.

Biol Chem. 2013 Jun;394(6):753-60. doi: 10.1515/hsz-2012-0309.

PMID:
23362192
28.

High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance.

Hohlfeld T, Saxena A, Schrör K.

Thromb Haemost. 2013 May;109(5):825-33. doi: 10.1160/TH12-07-0532. Epub 2012 Dec 13. Review.

PMID:
23238666
29.
30.

A novel function of FoxO transcription factors in thrombin-stimulated vascular smooth muscle cell proliferation.

Mahajan SG, Fender AC, Meyer-Kirchrath J, Kurt M, Barth M, Sagban TA, Fischer JW, Schrör K, Hohlfeld T, Rauch BH.

Thromb Haemost. 2012 Jul;108(1):148-58. doi: 10.1160/TH11-11-0756. Epub 2012 May 3.

PMID:
22552808
31.

[New antiplatelet agents and the question of dual antiplatelet therapy].

Schrör K.

Internist (Berl). 2012 Mar;53(3):351-6. doi: 10.1007/s00108-011-2998-x. German.

PMID:
22349172
32.

[Essential acetylsalicylic acid: over 100 years old and still good for surprises (interview by Dr. med. Jochen Aumiller)].

Schrör K.

MMW Fortschr Med. 2011 Jan 20;153(3):16. German. No abstract available.

PMID:
22165596
33.

Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.

Schrör K.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):473-84. doi: 10.1016/j.bpg.2011.10.016. Review.

PMID:
22122764
34.

Aspirin in the chemoprevention of colorectal neoplasia: an overview.

Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, Logan RF, Rothwell PM, Schrör K, Baron JA.

Cancer Prev Res (Phila). 2012 Feb;5(2):164-78. doi: 10.1158/1940-6207.CAPR-11-0391. Epub 2011 Nov 14. Review.

35.

[Acetylsalicylic acid for primary cardiovascular prevention dependent on the role of the ankle brachial index].

Schrör K, Nitschmann S.

Internist (Berl). 2011 Oct;52(10):1256-8. doi: 10.1007/s00108-011-2941-1. German. No abstract available.

PMID:
21901406
36.

Pharmacokinetic basis of the antiplatelet action of prasugrel.

Schrör K, Siller-Matula JM, Huber K.

Fundam Clin Pharmacol. 2012 Feb;26(1):39-46. doi: 10.1111/j.1472-8206.2011.00986.x. Epub 2011 Sep 5. Review.

PMID:
21895761
37.

Redox regulation of human protease-activated receptor-2 by activated factor X.

Jobi K, Rauch BH, Dangwal S, Freidel K, Doller A, Eberhardt W, Fischer JW, Schrör K, Rosenkranz AC.

Free Radic Biol Med. 2011 Nov 1;51(9):1758-64. doi: 10.1016/j.freeradbiomed.2011.08.003. Epub 2011 Aug 12.

PMID:
21871560
38.

Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.

Höchtl T, Tentzeris I, Schrör K, Huber K.

Fundam Clin Pharmacol. 2012 Feb;26(1):2-10. doi: 10.1111/j.1472-8206.2011.00985.x. Epub 2011 Aug 10. Review.

PMID:
21831128
39.

Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells.

Rosenkranz AC, Schrör K, Rauch BH.

Thromb Haemost. 2011 Sep;106(3):561-2. doi: 10.1160/TH11-04-0275. Epub 2011 Jul 28. No abstract available.

PMID:
21800011
40.

Regulation of human vascular protease-activated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T cells (NFAT).

Rosenkranz AC, Rauch BH, Doller A, Eberhardt W, Böhm A, Bretschneider E, Schrör K.

Mol Pharmacol. 2011 Aug;80(2):337-44. doi: 10.1124/mol.111.072850. Epub 2011 May 19.

PMID:
21596928
41.

Genetic variability in response to clopidogrel therapy and its clinical implications.

Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K.

Thromb Haemost. 2011 May;105 Suppl 1:S55-9. doi: 10.1160/THS10-11-0747. Epub 2011 Apr 11. Review.

PMID:
21479337
42.

Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.

Kaber G, Kaiser B, Baumgärtel-Allekotte D, Rauch B, Nossmann S, Heim Kh, Weber A, Nagy N, Fischer J, Schrör K.

Br J Pharmacol. 2011 Sep;164(2b):561-9. doi: 10.1111/j.1476-5381.2011.01392.x.

43.

Microglia activation in hepatic encephalopathy in rats and humans.

Zemtsova I, Görg B, Keitel V, Bidmon HJ, Schrör K, Häussinger D.

Hepatology. 2011 Jul;54(1):204-15. doi: 10.1002/hep.24326.

PMID:
21452284
44.

Cholesterol induces apoptosis-associated loss of the activated leukocyte cell adhesion molecule (ALCAM) in human monocytes.

Rauch SJ, Rosenkranz AC, Böhm A, Meyer-Kirchrath J, Hohlfeld T, Schrör K, Rauch BH.

Vascul Pharmacol. 2011 Mar-Jun;54(3-6):93-9. doi: 10.1016/j.vph.2011.03.004. Epub 2011 Mar 31.

PMID:
21440089
45.

Functional testing methods for the antiplatelet effects of aspirin.

Schrör K, Huber K, Hohlfeld T.

Biomark Med. 2011 Feb;5(1):31-42. doi: 10.2217/bmm.10.122. Review.

PMID:
21319963
46.

Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation.

Ulrych T, Böhm A, Polzin A, Daum G, Nüsing RM, Geisslinger G, Hohlfeld T, Schrör K, Rauch BH.

J Thromb Haemost. 2011 Apr;9(4):790-8. doi: 10.1111/j.1538-7836.2011.04194.x.

47.

High glucose enhances thrombin responses via protease-activated receptor-4 in human vascular smooth muscle cells.

Dangwal S, Rauch BH, Gensch T, Dai L, Bretschneider E, Vogelaar CF, Schrör K, Rosenkranz AC.

Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):624-33. doi: 10.1161/ATVBAHA.110.219105. Epub 2010 Dec 16.

PMID:
21164077
48.

Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions.

Rauch BH, Rosenkranz AC, Ermler S, Böhm A, Driessen J, Fischer JW, Sugidachi A, Jakubowski JA, Schrör K.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2434-42. doi: 10.1161/ATVBAHA.110.213702. Epub 2010 Nov 11.

PMID:
21071695
49.

Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.

Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K.

J Thromb Haemost. 2010 Dec;8(12):2624-41. doi: 10.1111/j.1538-7836.2010.04049.x. Review.

50.

Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Siller-Matula JM, Huber K, Christ G, Schrör K, Kubica J, Herkner H, Jilma B.

Heart. 2011 Jan;97(2):98-105. doi: 10.1136/hrt.2010.195438. Epub 2010 Aug 23. Review.

PMID:
20736210

Supplemental Content

Loading ...
Support Center